Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
OGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.25 - $23.10
Previous CloseN/A
Volume728.75K
Average Volume (3M)4.61M
Market Cap
$2.46B
Enterprise Value$12.24B
Total Cash (Recent Filing)$675.00M
Total Debt (Recent Filing)$8.88B
Price to Earnings (P/E)2.8
Beta0.53
Next Earnings
Aug 12, 2025EPS Estimate
0.89Next Dividend Ex-Date
May 12, 2025Dividend Yield8.66%
Share Statistics
EPS (TTM)3.33
Shares Outstanding259,956,050
10 Day Avg. Volume4,483,696
30 Day Avg. Volume4,605,231
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.29
Enterprise Value/Ebitda7.41
Forecast
1Y Price Target
$17.83Price Target Upside88.68% Upside
Rating ConsensusHold
Number of Analyst Covering7
---
Organon News
---
Bulls Say, Bears Say
Bulls Say
New Product LaunchOrganon's new product launch Vtama has reported good sales figures, boosting confidence in its market potential.
Sales GrowthPositive tailwinds include approximately $280 million in sales growth from VTAMA, Emgality, and women's health brands Nexplanon and fertility.
Bears Say
Currency RiskSeventy-five percent of OGN revenue is ex-US, so a strengthening USD could also create a currency headwind.
Dividend CutOrganon has significantly reduced its dividend from $0.28/share to $0.08/share, a drop of over 70%, surprising the market.
Leverage FocusInvestor feedback is pushing Organon to focus more on leverage rather than maintaining their previous dividend levels, indicating financial stress.
---
Ownership Overview
0.32% Insiders
21.25% Mutual Funds
0.98% Other Institutional Investors
50.99% Public Companies and
Individual Investors
OGN FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was $9.25 and its highest was $23.10 in the past 12 months.
What is Organon’s market cap?
Organon’s market cap is $2.46B.
When is Organon’s upcoming earnings report date?
Organon’s upcoming earnings report date is Aug 12, 2025 which is in 101 days.
How were Organon’s earnings last quarter?
Organon released its earnings results on May 01, 2025. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.894 by $0.126.
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Undervalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of $0.019 which represents an annual dividend yield of 8.66%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate is 0.89.
How many shares outstanding does Organon have?
Organon has 259,956,050 shares outstanding.
What happened to Organon’s price movement after its last earnings report?
Organon reported an EPS of $1.02 in its last earnings report, beating expectations of $0.894. Following the earnings report the stock price went down -26.914%.
Which hedge fund is a major shareholder of Organon?
Currently, no hedge funds are holding shares in OGN
---
Organon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$17.83 (88.68% Upside)
$17.83 (88.68% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 91%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.52%
12-Months-Change
Fundamentals
Return on Equity
429.85%
Trailing 12-Months
Asset Growth
8.65%
Trailing 12-Months
Company Description
Organon
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
---
OGN Company Deck
---
OGN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of strong growth in certain key products and segments, alongside challenges such as revenue decline due to loss of exclusivity and pricing pressures. The company's focus on cost efficiency and deleveraging initiatives is aimed at strengthening its financial position. While there are positive developments such as the successful launch and growth of certain products, the financial challenges and external pressures balance the overall sentiment.Read More>---
OGN Stock 12 Month Forecast
Average Price Target
$17.83
▲(88.68% Upside)
Technical Analysis
---